Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | CCNC | P24863 | 3/20 | 0.38 |
| ▸ | CDK8 | P49336 | 3/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12489868 | 0.90 | EIF2AK2 (0.39) | EIF2AK2IKBKBCCNCCDK8EZH2 | |
| SCHEMBL2180495 | 0.88 | EIF2AK2 (0.38) | EIF2AK2IKBKBCCNCCDK8EZH2 | |
| SCHEMBL12486630 | 0.87 | CCNC (0.38) | EIF2AK2IKBKBCCNCCDK8EZH2 | |
| SCHEMBL2179297 | 0.86 | EIF2AK2 (0.41) | EIF2AK2CCNCCDK8EZH2MKNK1 | |
| SCHEMBL6126567 | 0.86 | IKBKB (0.48) | EIF2AK2IKBKBEZH2MKNK1EHMT1 | |
| SCHEMBL2178208 | 0.85 | EZH2 (0.40) | EIF2AK2IKBKBCCNCCDK8EZH2 | |
| SCHEMBL2180218 | 0.85 | ALDH1A1 (0.44) | EIF2AK2CCNCCDK8EZH2MKNK1 | |
| SCHEMBL2178619 | 0.85 | EZH2 (0.41) | EIF2AK2IKBKBCCNCCDK8EZH2 | |
| SCHEMBL2178581 | 0.84 | CCNC (0.41) | EIF2AK2CCNCCDK8MKNK1 | |
| SCHEMBL2179393 | 0.84 | EHMT1 (0.40) | EIF2AK2IKBKBCCNCCDK8EZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| WO-2011082268-A2 | SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS | ARQULE INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | EIF2AK2 1269/4885IKBKB 401/4885CCNC 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.